Pharma News
Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.
Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)
Thursday, September 26, 2019Blade Therapeutics a biopharmaceutical company advancing novel antifibrotic therapies today announced the acquisition of ATXCo Inc including its core asset PAT a Phase I ready autotaxin inhibitor for patients with fibrotic diseases
NeuCyte Licenses Promising Novel Compound for Treatment of Refractory Epilepsy and Related Neurological Disorders
Thursday, September 26, 2019NeuCyte Inc an innovative biotech company focused on developing novel treatments for neurological disorders today announced that it has entered into an exclusive license agreement with Trillium Therapeutics to advance an undisclosed preclinical compo...
ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics
Wednesday, September 25, 2019IMMUNOPRECISE ANTIBODIES LTD an industry leader in the discovery of novel therapeutic antibodies announces that Talem Therapeutics its whollyowned subsidiary has entered into an LOI to form a Joint Venture as it partners in the continued development...
Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options
Wednesday, September 25, 2019The Ivy Brain Tumor Center at Barrow Neurological Institute today announced a new collaboration with QED Therapeutics Inc a subsidiary of BridgeBio Pharma Inc NasdaqBBIO to investigate the FGFR tyrosine kinase inhibitor infigratinib for the treatment...
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab)
Tuesday, September 24, 2019IMab Biopharma IMab a China and USbased clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential firstinclass and bestinclass biologics in immunooncology and autoimmune diseases today announced that...
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs
Tuesday, September 24, 2019Anchiano Therapeutics Ltd a pivotalstage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer today reported that Anchiano Therapeutics Inc the Companys US subsidiary has entered into an exclusive w...
Newron Pharmaceuticals: Commercialization Partner Meiji Seika Together with Eisai Announce the Approval of Safinamide for Parkinson’s Disease in Japan
Monday, September 23, 2019Newron Pharmaceuticals SpA a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system is pleased to note its partner Meiji Seika Pharma Co Ltd together with Eisai...
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Saturday, September 21, 2019Boehringer Ingelheim and Inflammasome Therapeutics Inc Inflammasome today announced they have entered into a codevelopment and license agreement to develop up to three therapies for patients with retinal diseases By combining Inflammasomes unique int...
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Friday, September 20, 2019Allogene Therapeutics Inc a clinicalstage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer today announced that it has entered into a research collaboration agreement with Stanford University to investigate a...
Y-Trap Enters Collaboration with Merck KGaA,to Develop Novel Antibody-Ligand Traps for Immuno-Oncology
Friday, September 20, 2019YTrap Inc has signed a collaboration and license agreement with Merck KGaA Darmstadt Germany a leading science and technology company for the exclusive development of multiple specific antibodyligand traps for cancer immunotherapy
